Entera Bio Ltd.

Entera Bio Ltd. is a clinical-stage biotechnology company developing oral tablet versions of peptide and protein replacement therapies. Its lead work centers on the N-Tab platform and first-in-class oral programs in osteoporosis and metabolic disease, including EB613, EB612, and oral GLP-1/GLP-2-related candidates.

−27 378,6 %

−27 235,7 %

−76,8 %

6.94

6.94

— Entera Bio Ltd.
%
Oral peptide therapeutics0% Development of oral tablet formulations designed to replace injectable peptide and protein therapies.
Lead clinical programs0% EB613, EB612 and oral OXM programs targeting osteoporosis and metabolic disease.
Platform technology0% N-Tab™ delivery technology used to enable oral administration of biologics.
Collaborative research services100% Contract research and material transfer services performed for third parties.

Entera does not yet sell approved products to commercial end customers; its current economic counterparties are...

  • Research collaboration counterpartiesprimary

    Third parties that pay for material transfer and research services while Entera performs contract R&D work.

  • Future osteoporosis patients and physiciansemerging

    Potential users of EB613 if approved, seeking an oral alternative to injectable PTH therapy.

  • Future metabolic disease patients and physiciansemerging

    Potential users of oral GLP-1/Glucagon or GLP-2 therapies if the programs reach commercialization.

  • Strategic pharma partnerssecondary

    Partners that may license, co-develop, or fund oral peptide programs to access the platform.

Entera’s operations are centered in Jerusalem, Israel, where all employees are based and core R&D work is performed...

  • •Jerusalem, Israel is the main operating and R&D base
  • •All employees are based in Israel
  • •Advisors are located in the United States, UK, Europe and Asia
  • •Contract manufacturing is performed through a UK-based CMO
  • •Clinical and regulatory work is international, reducing single-country dependence

Entera is focused on advancing first-in-class oral versions of peptide therapies that are normally delivered by...

01
Advance EB613 toward phase 3short-term

EB613 is the most advanced program and could validate the platform in a large osteoporosis market.

02
Progress oral OXM with OPKOshort-term

The collaboration can expand the pipeline into metabolic disease while sharing development burden.

03
Extend N-Tab platform valuemedium-term

Platform validation across multiple peptides can improve partnering leverage and long-term optionality.

04
Secure non-dilutive or strategic fundingshort-term

Clinical development requires capital and the company has stated additional funding will be needed.

Entera is a pre-revenue clinical-stage company, so execution risk is concentrated in clinical outcomes, regulatory...

high

Clinical development failure

EB613, EB612 and oral OXM are still in development and may not demonstrate safety or efficacy.

Scope
Lead pipeline programs
Materiality
high
high

Financing risk

The company expects to need additional capital before commercialization and may not raise it on favorable terms.

Scope
Operating runway and trial funding
Materiality
high
high

Geopolitical risk in Israel

Employees and operations are based in Israel, so conflict could disrupt work, supply chains, or fundraising.

Scope
Jerusalem operations and personnel
Materiality
high
high

Regulatory risk

The company needs FDA and other regulatory alignment before advancing into later-stage trials and approval.

Scope
EB613 phase 3 planning
Materiality
high
medium

Partner and collaboration risk

Development timelines and economics depend partly on third-party collaboration agreements.

Scope
OPKO collaboration and research services
Materiality
medium
Over-time revenue recognition for research services
Quarterly revenue can be small and uneven
Grant-related royalty and repayment obligations
Potential contingent liability and cash outflow
Clinical-stage expense recognition
Material effect on reported earnings and burn rate
Share-based compensation
Affects R&D and G&A expense

Entrada Therapeutics, Inc.

TRDA · Pharmaceutical Preparations

ENDRA Life Sciences Inc.

NDRA · Electromedical & Electrotherapeutic Apparatus

Lyra Therapeutics, Inc.

LYRA · Surgical & Medical Instruments & Apparatus

ESTABLISHMENT LABS HOLDINGS INC.

ESTA · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Innoviva, Inc.

INVA · Pharmaceutical Preparations

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

: 28.4.2026